NetworkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present KROS-101 Research at Discovery on Target Conference

Kairos Pharma (NYSE American: KAPA) announced that President and Chief Scientific Officer Neil Bhowmick will present and moderate a discussion at the 24th Annual Discovery on Target Drug Discovery Conference, being held Sept. 28-Oct. 1 in Boston. Bhowmick will moderate a Sept. 30 breakout session titled “Winning the Race against Cancer Therapy Resistance,” focused on Kairos strategy of targeting cancer drug resistance to extend the efficacy of previously effective drug candidates.

Bhowmick will also deliver an oral plenary presentation Sept. 30 at 2:35 p.m. Eastern on KROS-101, Kairos drug candidate targeting solid tumors. The presentation will focus on KROS-101 targeting of GITR (“Glucocorticoid-Induced TNF Receptor”) to increase T-cell function and expand effector T-cells with anti-tumor activity.

To view the full press release, visit https://nnw.fm/DoHxL

About Kairos Pharma Ltd.

Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Kairos Pharma’s lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.

NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company’s newsroom at https://nnw.fm/KAPA

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
[email protected]

NetworkNewsWire is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is NetworkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present KROS-101 Research at Discovery on Target Conference.